Reviva Pharmaceuticals Holdings, Inc. (RVPH) — SC 13D/A Filings
All SC 13D/A filings from Reviva Pharmaceuticals Holdings, Inc.. Browse 3 SC 13D/A reports with AI-powered summaries and risk analysis.
SC 13D/A Filings (3)
-
Bhat Amends Reviva Pharma Stake Filing
— Aug 23, 2024 Risk: medium
Laxminarayan Bhat, CEO of Reviva Pharmaceuticals Holdings, Inc., filed an amendment (SC 13D/A) on August 23, 2024, related to his beneficial ownership of the co -
Vedanta Partners Adjusts Stake in Reviva Pharmaceuticals
— May 31, 2024 Risk: medium
Vedanta Partners, LLC, through its filing on May 31, 2024, has amended its Schedule 13D/A regarding Reviva Pharmaceuticals Holdings, Inc. The filing indicates a -
Bhat Laxminarayan Amends Reviva Pharma Holdings
— Feb 16, 2024 Risk: low
Bhat Laxminarayan filed an amended Schedule 13D/A on February 16, 2024, regarding his holdings in Reviva Pharmaceuticals Holdings, Inc. The filing indicates a c
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX